Performance of Endoscopic Sleeve Gastroplasty by Obesity Class in the United States Clinical Setting.

Autor:	Gala K; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Brunaldi V; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., McGowan C; True You Weight Loss, Cary, North Carolina, USA., Sharaiha RZ; Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York, USA., Maselli D; True You Weight Loss, Cary, North Carolina, USA., Vanderwel B; Eviva, Shoreline, Washington, USA., Kedia P; Methodist Dallas Medical Center, Dallas, Texas, USA., Ujiki M; NorthShore University Health System, Evanston, Illinois, USA., Wilson E; University of Texas Health Science Center-Houston, Houston, Texas, USA ., Vargas EJ; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Storm AC; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Abu Dayyeh BK; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Jazyk:	angličtina
Zdroj:	Clinical and translational gastroenterology [Clin Transl Gastroenterol] 2024 Jan 01; Vol. 15 (1), pp. e00647. Date of Electronic Publication: 2024 Jan 01.
DOI:	10.14309/ctg.0000000000000647
Abstrakt:	Introduction: Endoscopic sleeve gastroplasty (ESG) has gained popularity over the past decade and has been adopted in both academic and private institutions globally. We present outcomes of the largest cohort of patients from the United States undergoing ESG and evaluate these according to obesity class. Methods: We performed a retrospective analysis of adult patients who underwent ESG. Medical information was abstracted from the electronic record with weight records up to 2 years after ESG. Percent total body weight loss (%TBWL) at 6, 12, 18, and 24 months was calculated based on baseline weight at the procedure. SPSS (version 29.0) was used for all statistical analyses. Results: A total of 1,506 patients from 7 sites were included (501 Class I obesity, 546 Class II, and 459 Class III). Baseline demographics differed according to obesity class due to differences in age, body mass index (BMI), height, sex distribution, and race. As early as 6 months post-ESG, mean BMI for each class dropped to the next lower class and remained there through 2 years. %TWBL achieved in the Class III group was significantly greater when compared with other classes at all time points. At 12 months, 83.2% and 60.9% of patients had ≥10% and ≥15% TBWL for all classes. There were no differences in adverse events between classes. Discussion: Real-world data from a large cohort of patients of all BMI classes across the United States shows significant and sustained weight loss with ESG. ESG is safe to perform in a higher obesity class with acceptable midterm efficacy. (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu